Jun Ke

机构：Fujian Medical University, Hunan Normal University, AstraZeneca (Brazil), AstraZeneca (Poland), Fujian Provincial Hospital, AstraZeneca (Spain), Fujian Academy of Medical Sciences, AstraZeneca (United States), Fuzhou University · ORCID：0009-0004-6918-2807

发表论文 90 篇 · 总被引 1202 次 · h-index 14

代表论文

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024 · New England Journal of Medicine · 被引 440)
• Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (2024 · Journal of Clinical Oncology · 被引 107)
• Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial (2025 · Annals of Oncology · 被引 67)
• The neutrophil-to-lymphocyte ratio is associated with coronary heart disease risk in adults: A population-based study (2024 · PLoS ONE · 被引 32)
• Association between triglyceride glucose-waist to height ratio and coronary heart disease: a population-based study (2024 · Lipids in Health and Disease · 被引 20)
• Association of serum albumin levels and stroke risk in adults over 40 years: A population-based study (2023 · Medicine · 被引 13)